# A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP

> **NCT02741388** · PHASE1 · COMPLETED · sponsor: **The Lymphoma Academic Research Organisation** · enrollment: 39 (actual)

## Conditions studied

- B-cell Lymphoma

## Interventions

- **DRUG:** selinexor
- **DRUG:** Rituximab
- **DRUG:** Dexamethasone
- **DRUG:** Oxaliplatin
- **DRUG:** Cisplatin
- **DRUG:** Cytarabine
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT02741388
- **Lead sponsor:** The Lymphoma Academic Research Organisation
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10
- **Primary completion:** 2021-09-29
- **Final completion:** 2021-09-29
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2021-12-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02741388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02741388, "A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02741388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*